All In Biotech

Drug Trial Radar · NCT02216214

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

Last checked: Nov 20, 2026Latest source record: Nov 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 888 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

888

Actual

Start

Oct 7, 2014

Primary completion

Nov 29, 2017

Study completion Jan 2, 2018

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Aug 13, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to assess the efficacy, safety and tolerability of mirabegron versus placebo in the treatment of older adult subjects with OAB.

Conditions

  • Overactive Bladder (OAB)

Interventions

  • MirabegronDrug

    oral tablet

  • PlaceboDrug

    oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to End of Treatment (EOT) in Mean Number of Micturitions Per 24 HoursTime frame: Baseline and EOT (up to 12 weeks)
  2. Change From Baseline to EOT in Mean Number of Incontinence Episodes Per 24 HoursTime frame: Baseline and EOT (up to 12 weeks)

Locations

120 sites in 2 countries. Site status is shown where the registry gives one.

  • Site US00066

    Huntsville, Alabama

  • Site US00148

    Mobile, Alabama

  • Site US00009

    Anchorage, Alaska

  • Site US00020

    Tucson, Arizona

  • Site US00019

    Tucson, Arizona

  • Site US00063

    Little Rock, Arkansas

  • Site US00081

    Little Rock, Arkansas

  • Site US00176

    Anaheim, California

  • Site US00048

    Beverly Hills, California

  • Site US00142

    Beverly Hills, California

  • Site US00150

    Hawaiian Gardens, California

  • Site US00112

    Los Angeles, California

  • Site US00034

    Los Angeles, California

  • Site US00010

    Murrieta, California

  • Site US00135

    San Diego, California

  • Site US00139

    San Diego, California

  • Site US00144

    Santa Maria, California

  • Site US00083

    Stanford, California

  • Site US00026

    Colorado Springs, Colorado

  • Site US00039

    Denver, Colorado

  • Site US00004

    Denver, Colorado

  • Site US00040

    New London, Connecticut

  • Site US00090

    Washington D.C., District of Columbia

  • Site US00064

    Brooksville, Florida

  • Site US00080

    Coral Gables, Florida

  • Site US00002

    DeBary, Florida

  • Site US00001

    DeLand, Florida

  • Site US00017

    DeLand, Florida

  • Site US00018

    Edgewater, Florida

  • Site US00027

    Fleming Island, Florida

  • Site US00151

    Hialeah, Florida

  • Site US00179

    Jupiter, Florida

  • Site US00057

    Kissimmee, Florida

  • Site US00076

    Lakeland, Florida

  • Site US00037

    Miami, Florida

  • Site US00029

    Miami, Florida

  • Site US00042

    Miami, Florida

  • Site US00007

    North Miami, Florida

  • Site US00021

    Pompano Beach, Florida

  • Site US00035

    Port Orange, Florida

Showing 40 of 120 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.